GFM
ORIC icon

GF Fund Management’s Oric Pharmaceuticals ORIC Stock Holding History

GF Fund Management’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23K Sell
2,126
-50
-2% -$453 ﹤0.01% 471
2026
Q1 		$27.6K Buy
2,176
+263
+14% +$2.99K ﹤0.01% 463
2025
Q4 		$15.6K Sell
1,913
-177
-8% -$2.04K ﹤0.01% 533
2025
Q3 		$25.1K Buy
2,090
+283
+16% +$2.98K ﹤0.01% 462
2025
Q2 		$18.3K Hold
1,807
– – ﹤0.01% 509
2025
Q1 		$10.1K Buy
1,807
+325
+22% +$2.84K ﹤0.01% 563
2024
Q4 		$12K Buy
+1,482
New +$13.6K ﹤0.01% 522

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GF Fund Management's ORIC Position: Q2 2026 in Review

GF Fund Management reduced its Oric Pharmaceuticals (ORIC) stake by 2.3% in Q2 2026, selling an estimated $453 and leaving 2,126 shares worth $23K. The position accounts for ﹤0.01% of the portfolio, ranked #471.

GF Fund Management first reported a position in ORIC in Q4 2024 and has held it in 7 quarters since. The position peaked at $27.6K in Q1 2026. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • GF Fund Management held 2,126 shares of Oric Pharmaceuticals worth $23K as of Q2 2026.
  • GF Fund Management sold 50 Oric Pharmaceuticals shares in Q2 2026, an estimated $453.
  • Oric Pharmaceuticals made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #471 holding.
  • GF Fund Management first reported a position in Oric Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Oric Pharmaceuticals position peaked at $27.6K in Q1 2026.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.